Developer docs
API playgroundTry for free, no card

Search company profiles

Khondrion

Full company profile

uuid0002p84

Namestring
Khondrion
Legal namestring
Khondrion BV
Websiteurl
khondrion.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Khondrion is a clinical-stage biopharmaceutical company headquartered in Nijmegen, The Netherlands, developing therapies for primary mitochondrial diseases. Founded in 2014 by Prof. Jan Smeitink, the company is advancing sonlicromanol, a wholly owned, brain-penetrant small molecule with a unique triple mode of action: (1) redox modulation to restore cellular metabolism, (2) radical trapping to prevent ferroptotic cell death, and (3) selective mPGES-1 inhibition delivering anti-inflammatory effects. Sonlicromanol has received Orphan Drug Designation in both the US (for all inherited mitochondrial respiratory chain disorders) and the EU (for OXPHOS defects, MELAS, Leigh disease, and MIDD), plus FDA Rare Pediatric Disease Designation for MELAS. The compound is protected by patents granted in the US and EU covering the mPGES-1 anti-inflammatory mechanism, and Khondrion maintains a proprietary library of redox-modulating compounds for future pipeline indications.

The clinical pipeline centers on the pivotal Phase 3 KHENERFIN study (NCT06451757) in m.3243A>G primary mitochondrial disease, a 52-week registrational trial enrolling up to 220 adult patients across Europe, the UK, and the US at a dose of 90 mg twice daily as dispersible tablets. Supporting programs include the Phase 2 SON4PEM investigator-initiated study at Amsterdam UMC evaluating sonlicromanol for post-exertional malaise in post-COVID syndrome, the pediatric Phase 2 KHENERGYC study in children with genetically confirmed mitochondrial disease, and long-term data from the completed KHENERGYZE Phase 2b and ongoing KHENEREXT open-label extension, where patients have been dosed for over three years with improvements shown in NMDAS disease severity, fatigue, cognitive function, and mood. Clinical execution is anchored by Radboudumc and Amsterdam UMC, with a Scientific Advisory Board chaired by Sir Prof. Doug Turnbull.

Khondrion is privately held and pre-revenue, funded through non-dilutive grants (Netherlands Enterprise Agency Innovation Credit up to €5 million, EU Horizon 2020 SME Instrument Phase 2, EFRO), venture philanthropy (The Mito Fund, the venture philanthropy arm of UMDF), and Dutch patient foundations (Energy4All, Join4Energy, Road4Energy, Ride4Kids, Tim Foundation, Zeldzame Ziekten Fonds). The planned commercial model combines traditional hospital and specialty pharmacy distribution with territory-specific licensing, exemplified by the August 2025 exclusive licensing agreement with Medvisis Switzerland AG covering Switzerland and Liechtenstein. The company underwent a leadership transition in September 2025, appointing Jasper Levink (previously CFO and CBO) as CEO to succeed founder Jan Smeitink, who became Chairman of a newly formed five-member Supervisory Board.

Short descriptiontext

Khondrion is a clinical-stage biopharmaceutical company developing sonlicromanol, a brain-penetrant small molecule for primary mitochondrial diseases and post-COVID fatigue, currently advancing a pivotal Phase 3 trial in m.3243A>G patients across the US, UK, and Europe.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNijmegen, Netherlands
HQ citystring
Nijmegen
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biopharmaceutical, mitochondrial disease therapeutics, orphan drug development, redox modulators, rare disease pipeline
Industry1 code
PRIMARYHLAIAIAB
Enzyme Replacement & Metabolic Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SIC code1 code
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Clinical-Stage Biopharmaceutical Therapeutics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

As a clinical-stage biopharma company, Khondrion's primary anticipated revenue stream is from sales of approved pharmaceutical products, specifically sonlicromanol for primary mitochondrial diseases and potentially post-COVID fatigue. The company is in late-stage development (Phase 3) and preparing for commercialization.

khondrion.com
2Licensing and Distribution Agreements
TypeLicensing Royalties
Description

Khondrion generates revenue through licensing agreements granting commercialization rights to partners in specific territories. The company has entered an exclusive licensing agreement with Medvisis Switzerland AG for Switzerland and Liechtenstein, with potential for additional territorial partnerships.

khondrion.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Khondrion is a clinical-stage biopharmaceutical company developing sonlicromanol, a potentially first-in-class, brain-penetrant small molecule redox-modulator with a unique triple mode of action (reductive/oxidative distress modulation, anti-ferroptotic radical trapping, and selective mPGES-1 anti-inflammatory inhibition), for the treatment of primary mitochondrial diseases including m.3243A>G-related MELAS spectrum disorders and post-COVID fatigue with post-exertional malaise.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Improvement in NMDAS disease severity score up to 6 points after 52 weeks treatment vs. natural history increase of 0.47 points/year indicating disease deterioration
+3 more records
Product overview1 text field

Khondrion is a clinical-stage biopharmaceutical company with its lead product sonlicromanol, a potentially first-in-class brain-penetrant redox-modulator with anti-inflammatory properties targeting mitochondrial dysfunction. The company's clinical pipeline includes: the pivotal Phase 3 KHENERFIN study for m.3243A>G Primary Mitochondrial Disease; the SON4PEM Phase 2 study for post-COVID syndrome; the pediatric KHENERGYC Phase 2 study; and the completed KHENERGYZE Phase 2b study with its KHENEREXT open-label extension. The company is developing sonlicromanol as a potential treatment for primary mitochondrial diseases including MELAS spectrum disorders and post-COVID syndrome.

Product and service1 record
1Sonlicromanol
CategoryClinical-stage pharmaceutical drug candidate
Description

Potentially first-in-class, brain-penetrant small molecule redox-modulator with a triple mode of action (reductive/oxidative distress modulation, anti-ferroptotic radical trapping, and selective mPGES-1 anti-inflammatory inhibition). Being developed as an investigational oral therapy for primary mitochondrial diseases including m.3243A>G-related MELAS spectrum disorders and maternally inherited diabetes and deafness (MIDD), as well as post-COVID fatigue with post-exertional malaise. Dosed as 90 mg dispersible tablets twice daily in Phase 3.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-08-18
Description

Khondrion entered an exclusive licensing agreement with Medvisis Switzerland AG for the registration and commercialization of sonlicromanol in Switzerland and Liechtenstein for the treatment of Primary Mitochondrial Diseases. Medvisis receives exclusive rights to commercialize the product in its territory while Khondrion retains ownership of the underlying technology and development rights.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Khondrion collaborates with Radboud University Medical Center in Nijmegen for clinical trial execution. Dr. Mirian Jansen from the clinical metabolic department serves as principal investigator in the KHENERFIN Phase 3 study. The center has been involved in natural history studies and clinical development programs.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Khondrion and Amsterdam UMC announced a collaboration to initiate a Phase 2 clinical trial of sonlicromanol for post-COVID symptoms. Prof. Michele van Vugt serves as Principal Investigator of the SON4PEM study at Amsterdam UMC, supported by ZonMw funding.

4International Mito Patients (IMP)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

IMP is a global network of 25 national patient advocacy groups on 5 continents representing approximately 10,000 mitochondrial patients and their families. Khondrion collaborates with IMP for patient engagement, clinical trial support, and disease awareness initiatives. IMP Chair Paula Morandi expressed encouragement for the Phase 3 trial progress.

khondrion.com
5Scientific Advisory Board
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Khondrion established a Scientific Advisory Board with leading mitochondrial medicine experts including Sir Prof. Doug Turnbull (Chairman), Prof. Marni Falk, Prof. Michelangelo Mancuso, Prof. Shamima Rahman, Prof. Anu Suomalainen Wartiovaara, and Prof. Akira Ohtake. The board provides independent oversight, strategic guidance, and clinical development advice.

khondrion.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing mavodelpar (REN001) for primary mitochondrial myopathies and fatty acid oxidation disorders. Reneo is a directly comparable peer in the primary mitochondrial disease therapeutic space with a similarly staged asset.

TypeBroad incumbent
Description

Clinical and commercial-stage rare-disease biotech with multiple programs across genetic and metabolic disorders including mitochondrial conditions. A larger established player in the same orphan genetic-disease investment universe.

TypeEmerging player
Description

Clinical-stage gene therapy company developing lenadogene nolparvovec for Leber Hereditary Optic Neuropathy (LHON), a mitochondrial genetic disorder. Directly comparable as a mitochondrial-disease drug developer with a different (gene therapy) modality.

4Stealth BioTherapeutics
TypeDirect peer
Description

Stealth is a clinical-stage biotech developing elamipretide for primary mitochondrial disease including Barth syndrome and LHON. It is the most directly comparable peer, operating in the same mitochondrial-disease therapeutic area with a similar late-stage clinical asset and orphan regulatory strategy.

TypeDirect peer
Description

Swedish clinical-stage biotech developing KL1333 (now renamed) for primary mitochondrial disease. Abliva is a direct European mitochondrial-disease peer, running parallel registrational-stage programs in the same orphan indication.

TypeBroad incumbent
Description

Commercial-stage rare-disease company with a portfolio spanning Duchenne muscular dystrophy, aromatic L-amino acid decarboxylase deficiency, and Friedreich's ataxia. Comparable as a broad rare-genetic-disease incumbent with CNS/metabolic programs.

TypeBroad incumbent
Description

AstraZeneca's rare-disease unit commercializing Soliris, Strensiq, and Ultomiris across multiple ultra-rare metabolic and neurological disorders. Comparable as a large incumbent in the orphan drug commercial landscape that Khondrion would face or partner with at launch.

TypeBroad incumbent
Description

Commercial-stage rare-disease company (notably where Khondrion's CMO Dr. Tom Pulles previously led EMEA Medical Affairs). Comparable as a larger rare-disease player pursuing multiple orphan metabolic and neurological indications with global commercialization.

TypeEmerging player
Description

Clinical-stage biotech developing leriglitazone for X-linked adrenoleukodystrophy and Friedreich's ataxia. Comparable as a European late-stage rare-disease CNS/metabolic player with orphan drug designation.

10Zogenix (now UCB, formerly Larodopa path)
TypeOthers
Description

UCB acquired Zogenix in 2022 for Fintepla (Dravet syndrome). Comparable as a strategic acquirer / partner archetype for late-stage orphan CNS assets — a representative exit path for Khondrion at potential approval or partnering milestones.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Khondrion

Clinical-Stage Biopharmaceutical Therapeuticskhondrion.com

Khondrion is a clinical-stage biopharmaceutical company developing sonlicromanol, a brain-penetrant small molecule for primary mitochondrial diseases and post-COVID fatigue, currently advancing a pivotal Phase 3 trial in m.3243A>G patients across the US, UK, and Europe.

What Khondrion does

Khondrion is a clinical-stage biopharmaceutical company headquartered in Nijmegen, The Netherlands, developing therapies for primary mitochondrial diseases. Founded in 2014 by Prof. Jan Smeitink, the company is advancing sonlicromanol, a wholly owned, brain-penetrant small molecule with a unique triple mode of action: (1) redox modulation to restore cellular metabolism, (2) radical trapping to prevent ferroptotic cell death, and (3) selective mPGES-1 inhibition delivering anti-inflammatory effects. Sonlicromanol has received Orphan Drug Designation in both the US (for all inherited mitochondrial respiratory chain disorders) and the EU (for OXPHOS defects, MELAS, Leigh disease, and MIDD), plus FDA Rare Pediatric Disease Designation for MELAS. The compound is protected by patents granted in the US and EU covering the mPGES-1 anti-inflammatory mechanism, and Khondrion maintains a proprietary library of redox-modulating compounds for future pipeline indications.

The clinical pipeline centers on the pivotal Phase 3 KHENERFIN study (NCT06451757) in m.3243A>G primary mitochondrial disease, a 52-week registrational trial enrolling up to 220 adult patients across Europe, the UK, and the US at a dose of 90 mg twice daily as dispersible tablets. Supporting programs include the Phase 2 SON4PEM investigator-initiated study at Amsterdam UMC evaluating sonlicromanol for post-exertional malaise in post-COVID syndrome, the pediatric Phase 2 KHENERGYC study in children with genetically confirmed mitochondrial disease, and long-term data from the completed KHENERGYZE Phase 2b and ongoing KHENEREXT open-label extension, where patients have been dosed for over three years with improvements shown in NMDAS disease severity, fatigue, cognitive function, and mood. Clinical execution is anchored by Radboudumc and Amsterdam UMC, with a Scientific Advisory Board chaired by Sir Prof. Doug Turnbull.

Khondrion is privately held and pre-revenue, funded through non-dilutive grants (Netherlands Enterprise Agency Innovation Credit up to €5 million, EU Horizon 2020 SME Instrument Phase 2, EFRO), venture philanthropy (The Mito Fund, the venture philanthropy arm of UMDF), and Dutch patient foundations (Energy4All, Join4Energy, Road4Energy, Ride4Kids, Tim Foundation, Zeldzame Ziekten Fonds). The planned commercial model combines traditional hospital and specialty pharmacy distribution with territory-specific licensing, exemplified by the August 2025 exclusive licensing agreement with Medvisis Switzerland AG covering Switzerland and Liechtenstein. The company underwent a leadership transition in September 2025, appointing Jasper Levink (previously CFO and CBO) as CEO to succeed founder Jan Smeitink, who became Chairman of a newly formed five-member Supervisory Board.

Khondrion firmographics

Firmographics
Name
Khondrion
Legal name
Khondrion BV
Website
https://khondrion.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Khondrion is a clinical-stage biopharmaceutical company developing sonlicromanol, a brain-penetrant small molecule for primary mitochondrial diseases and post-COVID fatigue, currently advancing a pivotal Phase 3 trial in m.3243A>G patients across the US, UK, and Europe.
Ownership category
akta.pro rank

Khondrion industry classification

Industry
Product category
Clinical-Stage Biopharmaceutical Therapeutics
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAIAB
Enzyme Replacement & Metabolic Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Clinical-stage biopharmaceutical
  • Mitochondrial disease therapeutics
  • Orphan drug development
  • Redox modulators
  • Rare disease pipeline

Where Khondrion is headquartered

Location

Headquarters

HQ city
Nijmegen
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

Khondrion business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Product Sales: As a clinical-stage biopharma company, Khondrion's primary anticipated revenue stream is from sales of approved pharmaceutical products, specifically sonlicromanol for primary mitochondrial diseases and potentially post-COVID fatigue. The company is in late-stage development (Phase 3) and preparing for commercialization.
  2. Licensing and Distribution Agreements: Khondrion generates revenue through licensing agreements granting commercialization rights to partners in specific territories. The company has entered an exclusive licensing agreement with Medvisis Switzerland AG for Switzerland and Liechtenstein, with potential for additional territorial partnerships.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Khondrion product offering

Product offering

Core offering

Khondrion is a clinical-stage biopharmaceutical company developing sonlicromanol, a potentially first-in-class, brain-penetrant small molecule redox-modulator with a unique triple mode of action (reductive/oxidative distress modulation, anti-ferroptotic radical trapping, and selective mPGES-1 anti-inflammatory inhibition), for the treatment of primary mitochondrial diseases including m.3243A>G-related MELAS spectrum disorders and post-COVID fatigue with post-exertional malaise.

Product overview

Khondrion is a clinical-stage biopharmaceutical company with its lead product sonlicromanol, a potentially first-in-class brain-penetrant redox-modulator with anti-inflammatory properties targeting mitochondrial dysfunction. The company's clinical pipeline includes: the pivotal Phase 3 KHENERFIN study for m.3243A>G Primary Mitochondrial Disease; the SON4PEM Phase 2 study for post-COVID syndrome; the pediatric KHENERGYC Phase 2 study; and the completed KHENERGYZE Phase 2b study with its KHENEREXT open-label extension. The company is developing sonlicromanol as a potential treatment for primary mitochondrial diseases including MELAS spectrum disorders and post-COVID syndrome.

Differentiator

Problem solved

Functional benefit

Products and services

  • Sonlicromanol Potentially first-in-class, brain-penetrant small molecule redox-modulator with a triple mode of action (reductive/oxidative distress modulation, anti-ferroptotic radical trapping, and selective mPGES-1 anti-inflammatory inhibition). Being developed as an investigational oral therapy for primary mitochondrial diseases including m.3243A>G-related MELAS spectrum disorders and maternally inherited diabetes and deafness (MIDD), as well as post-COVID fatigue with post-exertional malaise. Dosed as 90 mg dispersible tablets twice daily in Phase 3.

Quantifiable outcome

  • Improvement in NMDAS disease severity score up to 6 points after 52 weeks treatment vs. natural history increase of 0.47 points/year indicating disease deterioration
  • +3 more outcomes

Companies that use Khondrion

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Khondrion technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Khondrion partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • Medvisis Switzerland AGcoreChannel Partner/ Reseller/ Distributor · 18 August 2025Khondrion entered an exclusive licensing agreement with Medvisis Switzerland AG for the registration and commercialization of sonlicromanol in Switzerland and Liechtenstein for the treatment of Primary Mitochondrial Diseases. Medvisis receives exclusive rights to commercialize the product in its territory while Khondrion retains ownership of the underlying technology and development rights.
  • RadboudumccoreStrategic or Co-development PartnerKhondrion collaborates with Radboud University Medical Center in Nijmegen for clinical trial execution. Dr. Mirian Jansen from the clinical metabolic department serves as principal investigator in the KHENERFIN Phase 3 study. The center has been involved in natural history studies and clinical development programs.
  • Amsterdam University Medical CentercoreStrategic or Co-development PartnerKhondrion and Amsterdam UMC announced a collaboration to initiate a Phase 2 clinical trial of sonlicromanol for post-COVID symptoms. Prof. Michele van Vugt serves as Principal Investigator of the SON4PEM study at Amsterdam UMC, supported by ZonMw funding.
  • International Mito Patients (IMP)coreStrategic or Co-development PartnerIMP is a global network of 25 national patient advocacy groups on 5 continents representing approximately 10,000 mitochondrial patients and their families. Khondrion collaborates with IMP for patient engagement, clinical trial support, and disease awareness initiatives. IMP Chair Paula Morandi expressed encouragement for the Phase 3 trial progress.
  • Scientific Advisory BoardcoreStrategic or Co-development PartnerKhondrion established a Scientific Advisory Board with leading mitochondrial medicine experts including Sir Prof. Doug Turnbull (Chairman), Prof. Marni Falk, Prof. Michelangelo Mancuso, Prof. Shamima Rahman, Prof. Anu Suomalainen Wartiovaara, and Prof. Akira Ohtake. The board provides independent oversight, strategic guidance, and clinical development advice.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Khondrion competitors and assessment

Company assessment

Direct peers

  • Reneo Pharmaceuticals: Clinical-stage biotech developing mavodelpar (REN001) for primary mitochondrial myopathies and fatty acid oxidation disorders. Reneo is a directly comparable peer in the primary mitochondrial disease therapeutic space with a similarly staged asset.
  • Stealth BioTherapeutics: Stealth is a clinical-stage biotech developing elamipretide for primary mitochondrial disease including Barth syndrome and LHON. It is the most directly comparable peer, operating in the same mitochondrial-disease therapeutic area with a similar late-stage clinical asset and orphan regulatory strategy.
  • Abliva (formerly NeuroVive Pharmaceutical): Swedish clinical-stage biotech developing KL1333 (now renamed) for primary mitochondrial disease. Abliva is a direct European mitochondrial-disease peer, running parallel registrational-stage programs in the same orphan indication.

Broad incumbents

  • BridgeBio Pharma: Clinical and commercial-stage rare-disease biotech with multiple programs across genetic and metabolic disorders including mitochondrial conditions. A larger established player in the same orphan genetic-disease investment universe.
  • PTC Therapeutics: Commercial-stage rare-disease company with a portfolio spanning Duchenne muscular dystrophy, aromatic L-amino acid decarboxylase deficiency, and Friedreich's ataxia. Comparable as a broad rare-genetic-disease incumbent with CNS/metabolic programs.
  • Alexion (AstraZeneca Rare Disease): AstraZeneca's rare-disease unit commercializing Soliris, Strensiq, and Ultomiris across multiple ultra-rare metabolic and neurological disorders. Comparable as a large incumbent in the orphan drug commercial landscape that Khondrion would face or partner with at launch.
  • Ultragenyx Pharmaceutical: Commercial-stage rare-disease company (notably where Khondrion's CMO Dr. Tom Pulles previously led EMEA Medical Affairs). Comparable as a larger rare-disease player pursuing multiple orphan metabolic and neurological indications with global commercialization.

Emerging players

  • GenSight Biologics: Clinical-stage gene therapy company developing lenadogene nolparvovec for Leber Hereditary Optic Neuropathy (LHON), a mitochondrial genetic disorder. Directly comparable as a mitochondrial-disease drug developer with a different (gene therapy) modality.
  • Minoryx Therapeutics: Clinical-stage biotech developing leriglitazone for X-linked adrenoleukodystrophy and Friedreich's ataxia. Comparable as a European late-stage rare-disease CNS/metabolic player with orphan drug designation.

Others

  • Zogenix (now UCB, formerly Larodopa path): UCB acquired Zogenix in 2022 for Fintepla (Dravet syndrome). Comparable as a strategic acquirer / partner archetype for late-stage orphan CNS assets — a representative exit path for Khondrion at potential approval or partnering milestones.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Khondrion social profiles

Digital presence

Khondrion compliance and trust

Trust signal

Compliance4 records

Khondrion financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Khondrion leadership team

Management profile

Number of profiles

Profiles8 records

Khondrion funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Khondrion M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Khondrion

What does Khondrion do?

Khondrion is a clinical-stage biopharmaceutical company developing sonlicromanol, a potentially first-in-class, brain-penetrant small molecule redox-modulator with a unique triple mode of action (reductive/oxidative distress modulation, anti-ferroptotic radical trapping, and selective mPGES-1 anti-inflammatory inhibition), for the treatment of primary mitochondrial diseases including m.3243A>G-related MELAS spectrum disorders and post-COVID fatigue with post-exertional malaise.

Is Khondrion a public or private company?

Khondrion is a private company. It is classified as venture growth investor backed and is currently operating.

When was Khondrion founded?

Khondrion was founded in 2014. It employs 11 to 50 people.

Where is Khondrion based?

Khondrion is headquartered in Nijmegen, Netherlands, in the Europe region.

How does Khondrion make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Distribution Agreements.

Who are Khondrion's main competitors?

Direct peers on record are Reneo Pharmaceuticals, Stealth BioTherapeutics and Abliva (formerly NeuroVive Pharmaceutical). Broad incumbents are BridgeBio Pharma, PTC Therapeutics, Alexion (AstraZeneca Rare Disease) and Ultragenyx Pharmaceutical. Emerging players are GenSight Biologics and Minoryx Therapeutics. Zogenix (now UCB, formerly Larodopa path) is listed as an others.

Does Khondrion have an API?

No public API is recorded for Khondrion.

What industry is Khondrion in?

Khondrion's product category is Clinical-Stage Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIAIAB, Enzyme Replacement & Metabolic Disorder Therapies. Its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireKhondrion Announces First Patient Dosed in Phase II Study Targeting Debilitating Post-COVID FatigueKhondrion announced the first patient has been dosed in the Phase II SON4PEM study evaluating sonlicromanol, a proprietary small molecule therapy targeting fatigue associated with post-exertional malaise in post-COVID syndrome. The randomized, double-blind, placebo-controlled trial at Amsterdam University Medical Center will enroll approximately 80 adult patients receiving either 90 mg sonlicromanol or placebo twice daily over 13 weeks, with the primary endpoint measuring fatigue reduction via the Fatigue Assessment Scale. There are currently no approved therapies specifically addressing PEM-related fatigue in post-COVID syndrome, representing a significant unmet medical need that this trial aims to address.BioSpaceKhondrion Announces First Patient Dosed in Phase II Study Targeting Debilitating Post-COVID FatigueKhondrion announced the first patient dosed in the Phase II SON4PEM study for sonlicromanol, targeting post-COVID fatigue. The randomized, double-blind trial at Amsterdam University Medical Center will enroll about 80 patients, with the primary endpoint being fatigue reduction measured by the Fatigue Assessment Scale.BioSpaceKhondrion Announces First Patient Dosed in Pivotal Phase 3 KHENERFIN Study of Sonlicromanol in Mitochondrial DNA 3243A>G Primary Mitochondrial DiseaseKhondrion announced the first patient dosed in its Phase 3 KHENERFIN study of sonlicromanol for m.3243A>G primary mitochondrial disease. The 52-week randomized, placebo-controlled trial will enroll up to 220 adult patients across Europe, the UK, and the US, with primary endpoints on fatigue and muscle weakness.Business Wire BlogKhondrion Announces First Patient Dosed in Pivotal Phase 3 KHENERFIN Study of Sonlicromanol in Mitochondrial DNA 3243A>G Primary Mitochondrial DiseaseKhondrion announced the first patient dosed in its Phase 3 KHENERFIN study of sonlicromanol for m.3243A>G primary mitochondrial disease. The 52-week randomized, placebo-controlled trial will enroll up to 220 adult patients, with primary endpoints on fatigue and muscle weakness.PR NewswireKhondrion Secures up to €5 Million Innovation Credit from Dutch Government plus Additional Funding from Current Investors to Advance Phase 3 Clinical Trial in m.3243A>G Primary Mitochondrial DiseaseKhondrion received up to €5 million in Dutch Innovation Credit and private investment to fund Wave 1 of its Phase 3 trial of sonlicromanol for m.3243A>G primary mitochondrial disease. The trial is expected to launch in H2-2025, aiming to deliver the first approved treatment for the condition.GlobeNewswireUMDF and Khondrion Announce The Mito Fund’s Investment in Khondrion to Support Development of One of the Most Advanced Drug Candidates for Primary Mitochondrial DiseaseThe United Mitochondrial Disease Foundation's Mito Fund invested in Khondrion, a Netherlands-based biopharmaceutical company developing therapies for primary mitochondrial disease. Khondrion is preparing to initiate a Phase III study of its lead drug candidate sonlicromanol for adult patients with the m.3243A>G mutation, which affects about 4.4 per 100,000 people. The investment follows Phase IIb data showing benefits in fatigue, pain, and balance.GlobeNewswireUMDF and Khondrion Announce The Mito Fund’s Investment in Khondrion to Support Development of One of the Most Advanced Drug Candidates for Primary Mitochondrial DiseaseThe Mito Fund invested in Khondrion to support its lead drug candidate sonlicromanol for primary mitochondrial disease. The company is preparing a Phase III trial for adult patients with the m.3243A>G mutation, which affects about 4.4 per 100,000 people. The investment follows Phase IIb data showing benefits in fatigue, pain, and balance.GlobeNewswireKhondrion receives FDA clearance of IND application for pivotal Phase 3 clinical trial of sonlicromanol for the treatment of primary mitochondrial diseaseKhondrion received FDA clearance for its IND application for sonlicromanol, a redox-modulator for primary mitochondrial disease. The pivotal Phase 3 trial will enroll 150 adult patients with the m.3243A>G mutation, targeting chronic fatigue and muscle weakness, and is expected to start in 2025.GlobeNewswireKhondrion announces publication in Brain of integrated Phase 2b program demonstrating disease-modifying potential of sonlicromanol in primary mitochondrial diseaseKhondrion published results from its Phase 2b program of sonlicromanol in the journal Brain, showing disease-modifying benefits in adults with m.3243A>G mitochondrial disease. The 28-day randomized trial and 52-week extension demonstrated improvements in fatigue, pain, balance, and quality of life, with better effects in patients with more severe baseline symptoms. The company plans a pivotal Phase 3 study.GlobeNewswireKhondrion appoints Jasper Levink as Chief Financial and Business OfficerKhondrion appointed Jasper Levink as Chief Financial and Business Officer, effective immediately. The company's lead asset, sonlicromanol, has completed four clinical trials and is preparing for registrational phase 3 studies. Levink will combine his role with his position as CEO of SixtyFour Therapeutics.